

United States Patent and Trademark Office

cle

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/768,030	30 02/02/2004		Yasuhiko Munakata	0760-0329P	7791
2292	7590	07/07/2005		EXAMINER	
BIRCH ST PO BOX 7		KOLASCH &	CHEN, STACY BROWN		
	ALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
				1648	
				DATE MAII ED: 07/07/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/768,030	MUNAKATA ET AL.					
Office Action Summary	Examiner	Art Unit					
	Stacy B. Chen	1648					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period was reply to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 29 Ap	<u>oril 2005</u> .						
<u> </u>	action is non-final.						
3) Since this application is in condition for allowar closed in accordance with the practice under E							
Disposition of Claims							
 4) ☐ Claim(s) 1-14 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-14 are subject to restriction and/or expressions. 	vn from consideration.						
Application Papers							
9) ☐ The specification is objected to by the Examine	r.	,					
	The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the							
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Expression 11.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage					
Attachment/s)							
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) DNotice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application (PTO-152)					

DETAILED ACTION

1. Applicant's election with traverse of Group I, claims 1-10, filed April 29, 2005 is acknowledged. Upon further consideration of the claims, specifically claim 9 and 10, the restriction requirement of April 5, 2005 is withdrawn and a new restriction requirement is set forth below. The Office sincerely regrets any inconvenience to Applicant.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-8, drawn to a receptor for human parvovirus B19, classified in class 424, subclass 185.1.
 - II. Claims 9 and 10, drawn to an antibody that binds a receptor for human parvovirusB19, class 424, subclass 130.1
 - III. Claims 11-14, drawn to a method for producing a cell that expresses a receptor for human parvovirus B19, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are distinct products, drawn to a receptor and an antibody. These two products are structurally different. The structure of an antibody is complex, comprising variable and constant regions of light and heavy chains. The structure of the receptor does not share these features. It would be a serious burden to search both products, as a search for the receptor will not necessarily reveal antibodies that bind parvovirus B19.

Application/Control Number: 10/768,030

Art Unit: 1648

- Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product can be made by a materially different method. The receptor can be made synthetically as opposed to being expressed from nucleic acid in a vector (cell). It would be a serious burden to search both the product and process of making it. For example, a search for the receptor may reveal literature directed solely to the receptor and the various amino acid modifications that can be made (according to claim 1). The literature may reveal the different effects of the modifications on binding capabilities and affinities, without addressing the various methods of producing the receptor.
- Inventions II and III are unrelated. The antibody of Group II is not required to practice the method of Group III. A search for the antibody and a method of expressing a receptor on a cell would be a serious burden because the two inventions do not overlap in any way. Literature that speaks to the antibodies of B19 are not expected to reveal methods of expressing B19 receptors.

Because these inventions are distinct for the reasons given above and the literature search required for one Group is not required for any other Group, and therefore a serious burden, restriction for examination purposes as indicated is proper. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/768,030 Page 4

Art Unit: 1648

- 3. In order to respond to Applicant's arguments regarding the restriction requirement of April 5, 2005, the following remarks are made. Applicant argues that there is no undue burden placed on the examiner to search and consider all claims in their entirety. In response, there is a serious burden of search when considering all the claims. Applicant has not pointed to any specific reason why the search and examination of all claims would not place undue burden on the examiner. Applicant indicates that the method claims should be rejoined with product claims, should the product claims be allowable, and in accordance with the procedures outlined in the Restriction requirement of April 5, 2005 (and below).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Application/Control Number: 10/768,030 Page 5

Art Unit: 1648

5. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

6. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/768,030

Art Unit: 1648

Page 6

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James C. Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Stacy B. Chen
July 5, 2005